Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for SPRY
| Stock Name | Silverback Therapeutics Inc |
| Ticker | SPRY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US82835W1080 |
Show aggregate SPRY holdings
News associated with SPRY
- XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages
- Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47
- Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46
- Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53
- ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen
- Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51
- Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58
- Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG
- Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp
- Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN
- Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50
- Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55
- Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56
- Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48
- Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52
- Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
- Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50
- Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48
iShares MSCI World Small Cap UCITS ETF USD (Acc) SPRY holdings
| Date | Number of SPRY Shares Held | Base Market Value of SPRY Shares | Local Market Value of SPRY Shares | Change in SPRY Shares Held | Change in SPRY Base Value | Current Price per SPRY Share Held | Previous Price per SPRY Share Held |
|---|
| 2025-10-15 (Wednesday) | 29,118 | USD 319,424 | USD 319,424 | | | | |
| 2025-10-10 (Friday) | 28,917 | USD 327,340 | USD 327,340 | | | | |
| 2025-10-08 (Wednesday) | 28,917 | USD 321,268 | USD 321,268 | | | | |
| 2025-10-07 (Tuesday) | 28,917 | USD 298,713 | USD 298,713 | 134 | USD 3,112 | USD 10.33 | USD 10.27 |
| 2025-10-06 (Monday) | 28,783 | USD 295,601 | USD 295,601 | 0 | USD -1,152 | USD 10.27 | USD 10.31 |
| 2025-10-03 (Friday) | 28,783 | USD 296,753 | USD 296,753 | 0 | USD 864 | USD 10.31 | USD 10.28 |
| 2025-10-02 (Thursday) | 28,783 | USD 295,889 | USD 295,889 | 0 | USD 5,469 | USD 10.28 | USD 10.09 |
| 2025-10-01 (Wednesday) | 28,783 | USD 290,420 | USD 290,420 | 0 | USD 1,151 | USD 10.09 | USD 10.05 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of SPRY by Blackrock for IE00BF4RFH31
Show aggregate share trades of SPRY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 134 | | | 10.330* | | 14.95 |
| 2025-09-08 | SELL | -264 | | | 10.700* | | 16.20 Profit of 4,278 on sale |
| 2025-08-15 | BUY | 126 | | | 14.530* | | 16.25 |
| 2025-07-14 | BUY | 252 | | | 17.900* | | 15.83 |
| 2025-06-30 | BUY | 252 | | | 17.450* | | 15.28 |
| 2025-06-25 | BUY | 378 | | | 17.260* | | 15.00 |
| 2025-06-20 | SELL | -64 | | | 15.800* | | 14.71 Profit of 941 on sale |
| 2025-06-12 | SELL | -520 | | | 14.400* | | 14.29 Profit of 7,429 on sale |
| 2025-06-02 | BUY | 195 | | | 14.460* | | 0.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of SPRY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 1,036,811 | 2,339 | 1,919,450 | 54.0% |
| 2025-09-18 | 517,150 | 2,816 | 987,030 | 52.4% |
| 2025-09-17 | 379,115 | 0 | 772,889 | 49.1% |
| 2025-09-16 | 623,491 | 3,700 | 1,009,540 | 61.8% |
| 2025-09-15 | 663,271 | 2,900 | 1,595,652 | 41.6% |
| 2025-09-12 | 577,300 | 0 | 1,228,781 | 47.0% |
| 2025-09-11 | 685,503 | 145,273 | 1,124,464 | 61.0% |
| 2025-09-10 | 556,371 | 0 | 984,013 | 56.5% |
| 2025-09-09 | 453,162 | 0 | 963,620 | 47.0% |
| 2025-09-08 | 859,020 | 224,358 | 2,428,498 | 35.4% |
| 2025-09-05 | 832,450 | 76,200 | 2,588,108 | 32.2% |
| 2025-09-04 | 957,847 | 22,360 | 2,125,953 | 45.1% |
| 2025-09-03 | 766,348 | 0 | 2,155,073 | 35.6% |
| 2025-09-02 | 861,442 | 11,887 | 2,040,774 | 42.2% |
| 2025-08-29 | 1,336,171 | 183,205 | 3,462,653 | 38.6% |
| 2025-08-28 | 547,909 | 1,125 | 1,082,195 | 50.6% |
| 2025-08-27 | 412,301 | 500 | 704,469 | 58.5% |
| 2025-08-26 | 553,146 | 2,580 | 775,647 | 71.3% |
| 2025-08-25 | 615,803 | 0 | 1,289,829 | 47.7% |
| 2025-08-22 | 1,207,260 | 601 | 1,546,063 | 78.1% |
| 2025-08-21 | 468,222 | 50,536 | 608,426 | 77.0% |
| 2025-08-20 | 671,679 | 26,441 | 1,106,645 | 60.7% |
| 2025-08-19 | 623,980 | 8,735 | 1,160,286 | 53.8% |
| 2025-08-18 | 382,356 | 1,900 | 673,955 | 56.7% |
| 2025-08-15 | 844,074 | 725 | 1,153,241 | 73.2% |
| 2025-08-14 | 1,133,778 | 22,500 | 1,427,337 | 79.4% |
| 2025-08-13 | 1,127,522 | 39,066 | 1,770,071 | 63.7% |
| 2025-08-12 | 787,913 | 0 | 995,285 | 79.2% |
| 2025-08-11 | 351,430 | 640 | 901,141 | 39.0% |
| 2025-08-08 | 132,685 | 0 | 238,497 | 55.6% |
| 2025-08-07 | 164,593 | 9,579 | 265,414 | 62.0% |
| 2025-08-06 | 240,878 | 103 | 378,523 | 63.6% |
| 2025-08-05 | 192,066 | 0 | 313,299 | 61.3% |
| 2025-08-04 | 293,472 | 9,962 | 499,573 | 58.7% |
| 2025-08-01 | 429,256 | 0 | 556,082 | 77.2% |
| 2025-07-31 | 291,624 | 0 | 421,552 | 69.2% |
| 2025-07-30 | 232,315 | 0 | 483,325 | 48.1% |
| 2025-07-29 | 172,573 | 430 | 276,477 | 62.4% |
| 2025-07-28 | 529,668 | 0 | 1,110,316 | 47.7% |
| 2025-07-25 | 643,378 | 0 | 1,004,276 | 64.1% |
| 2025-07-24 | 275,442 | 0 | 656,207 | 42.0% |
| 2025-07-23 | 235,466 | 0 | 569,671 | 41.3% |
| 2025-07-22 | 197,912 | 0 | 274,374 | 72.1% |
| 2025-07-21 | 184,000 | 0 | 266,530 | 69.0% |
| 2025-07-18 | 349,976 | 0 | 556,771 | 62.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.